FINWIRES · TerminalLIVE
FINWIRES

Research Alert: Dupixent And Newer Drugs Power Sanofi Q1 Beat; Focus Turns To Incoming Ceo

-- CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:

Sanofi's Q1 2026 results beat consensus, with sales of EUR10.5B (vs. the EUR10.3B consensus) growing 6.2% Y/Y or 13.6% at CER, while its business EPS of EUR1.88 beat the EUR1.80 consensus. Dupixent continued its strong trajectory with 30.8% CER growth, while new launches like Altuviiio grew 42.2% CER on patient switches from older treatments. Sanofi reiterated its 2026 guidance for high-single-digit sales growth at CER and business EPS growth slightly faster than sales, in line with consensus. We expect Dupixent and newer drugs to support the 2026 outlook. We continue to like Dupixent's strong growth and rising contribution from new launches, which should gradually reduce its revenue concentration risk. With limited patent expiry exposure until Dupixent's 2031 cliff, we view the long-term setup as positive. However, we view that near-term sentiment will depend on incoming CEO Belen Garijo's R&D strategy to improve execution and restore confidence after recent disappointing pipeline readouts.

Related Articles

Research

Research Alert: Thermo Fisher Scientific: Q1 Results Top Estimates As Clario Acquisition Closes

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:TMO delivered Q1 top- and bottom-line beats with adjusted EPS of $5.44 vs. the $5.15 consensus and revenue of $11.01B (+6% Y/Y), though organic growth remained modest at 1% as the $8.9B Clario acquisition contributed significantly to performance. Mixed segment performance showed Life Sciences Solutions strength at $2.64B (+13% Y/Y) with improved 36.2% margin benefiting from the Solventum acquisition, while Analytical Instruments faced flat revenue and significant margin compression to 20.7% from 23.2% the prior year reflecting ongoing equipment spending pressures. FCF surged to $825M from $373M, supporting return of capital to shareholders. TMO returned $3.0B through share repurchases and increased its dividend 10%. The company plans to update 2026 financial guidance during the upcoming earnings call. We believe the robust cash flow performance and disciplined capital allocation activities support TMO's operational resilience despite the challenging life sciences tools operating environment.

$TMO
Research

Research Alert: Kdp: Q1 Ahead Of Expectations; Company Split On Track

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:Keurig Dr Pepper (KDP) posted Q1 adjusted EPS of $0.39 vs. $0.42 (-7%), ahead of the $0.37 consensus. Net sales rose 9.4% Y/Y to $3.98B ($150M ahead of consensus), but gross margin contracted 180 basis points to 52.8% (20 bps above consensus). On a constant currency basis, net sales were up 8.1%, attributed to price realizations (+5.5%) and volume/mix (+2.6%). The U.S. Refreshment Beverages segment was the standout performer, with net sales rising 11.9% to $2.6B, led by volume/mix (+7.2%) and favorable net price realizations (+4.7%). The U.S. Coffee segment remained a drag on overall performance, with net sales declining 2.3% to $857M as volume/mix (-8.2%) more than offset net price realizations (+5.9%). KDP maintained prior 2026 guidance. This was a solid earnings release, with top- and bottom-line results exceeding consensus. With the JDE Peet's acquisition complete and plans for separation into two pure-play companies, management is now focused on positioning both entities for long-term success.

$KDP
Australia

LSI Industries Fiscal Q3 Adjusted EPS, Sales Rise; Shares Up Pre-Bell

LSI Industries (LYTS) reported fiscal third-quarter adjusted earnings Thursday of $0.28 per diluted share, up from $0.20 a year earlier.Three analysts polled by FactSet expected $0.18.Net sales for the quarter ended March 31 were $150.5 million, up from $132.5 million a year earlier.Three analysts surveyed by FactSet expected $138.7 million.The company maintained its quarterly dividend at $0.05 a share, payable May 12 to holders of record on May 4.Shares of the company rose 6.2% in Thursday premarket trading.

$LYTS